Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

NCT07067450 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

98

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG: Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab)
OTHER: Observation

Sponsor

Sichuan University